Home > Oncology > ESMO 2022 > Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared with docetaxel in previously treated NSCLC

Selective KRASG12C inhibitor sotorasib demonstrates superior PFS and ORR compared with docetaxel in previously treated NSCLC

Presented By
Dr Melissa Johnson, Sarah Cannon Research Institute, TN, USA
Conference
ESMO 2022
Trial
Phase 3, CodeBreak 200
Results from the phase 3 CodeBreak 200 trial show a significant improvement of progression-free survival (PFS) and overall response rate (ORR) of the selective KRASG12C inhibitor sotorasib versus docetaxel in previously treated patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). KRAS mutations have been associated with poor prognosis and occur in approximately 1 in 4 patients diagnosed with NSCLC, with KRASG12C harboured at approximately 11–16% [1]. Previously, the phase 1/2 CodeBreak 100 study (NCT03600883) showed promising PFS, ORR, and overall survival (OS) in patients with KRASG12C-mutated NSCLC treated with the (oral) selective KRASG12C inhibitor sotorasib [2]. The phase 3 CodeBreak 200 study (NCT04...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on